Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other financing activities (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other financing activities for 3 consecutive years, with $983000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities changed N/A to $983000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $983000.0, a N/A change, with the full-year FY2025 number at $10.4 million, changed N/A from a year prior.
  • Other financing activities was $983000.0 for Q4 2025 at Madrigal Pharmaceuticals, up from $75000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $983000.0 in Q4 2025 to a low of $75000.0 in Q2 2023.
  • A 3-year average of $446400.0 and a median of $213000.0 in 2023 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 91.53% in 2023; the steepest drop was 91.53% in 2023.
  • Madrigal Pharmaceuticals' Other financing activities stood at $886000.0 in 2022, then tumbled by 91.53% to $75000.0 in 2023, then soared by 1210.67% to $983000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Other financing activities are $983000.0 (Q4 2025), $75000.0 (Q3 2023), and $75000.0 (Q2 2023).